Barrett Esophagus and Esophageal Adenocarcinoma

Textbook of Gastroenterology, Fifth Edition

Volumn 1, Issue , 2009, Pages 826-848

  Spechler, Stuart Jon ^a   Souza, Rhonda F ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Barrett esophagus and esophageal adenocarcinoma; Barrett esophagus and esophageal adenocarcinoma epidemiology; Barrett esophagus diagnosis; Barrett esophagus history roots of controversies; Dysplasia in Barrett esophagus; Endoscopic surveillance for dysplasia; Intestinal metaplasia at gastroesophageal junction; Metaplasia pathogenesis in esophagus; Molecular biology of dysplasia and adenocarcinoma in Barrett esophagus

Indexed keywords

EID: 84890008920     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781444303254.ch35     Document Type: Chapter

References (267)

1. Spechler SJ. Barrett's esophagus. N Engl J Med 2002; 346: 836.
2. Lagergren J, Bergstrom R, Lindgren A, Nyren O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 1999; 340: 825.
3. Pohl H, Welch HG. The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst 2005; 97: 142.
4. Barrett NR. Chronic peptic ulcer of the oesophagus and "oesophagitis". Br J Surg 1950; 38: 175.
5. Moersch RN, Ellis FH, McDonald JR. Pathologic changes occurring in severe reflux esophagitis. Surg Gynecol Obstet 1959; 108: 476.
6. Spechler SJ, Goyal RK. The columnar lined esophagus, intestinal metaplasia, and Norman Barrett. Gastroenterology 1996; 110: 614.
7. Paull A, Trier JS, Dalton MD, et al. The histologic spectrum of Barrett's esophagus. N Engl J Med 1976; 295: 476.
8. McClave SA, Boyce HW, Jr, Gottfried MR. Early diagnosis of columnar-lined esophagus: a new endoscopic criterion. Gastrointest Endosc 1987; 33: 413.
9. Spechler SJ, Zeroogian JM, Antonioli DA, et al. Prevalence of metaplasia at the gastro-oesophageal junction. Lancet 1994; 344: 1533.
10. Spechler SJ. The columnar lined oesophagus: a riddle wrapped in a mystery inside an enigma. Gut 1997; 41: 710.
11. Sharma P, Morales TG, Sampliner RE. Short segment Barrett's esophagus. The need for standardization of the definition and of endoscopic criteria. Am J Gastroenterol 1998; 93: 1033.
12. Haggitt RC, Tryzelaar J, Ellis FH, Colcher H. Adenocarcinoma complicating columnar epithelium-lined (Barrett's) esophagus. Am J Clin Pathol 1978; 70: 1.
13. Reid BJ, Weinstein WM. Barrett's esophagus and adenocarcinoma. Annu Rev Med 1987; 38: 477.
14. Reid BJ. Barrett's esophagus and esophageal adenocarcinoma. Gastroenterol Clin N Am 1991; 20: 817.
15. Weinstein WM, Ippoliti AF. The diagnosis of Barrett's esophagus: goblets, goblets, goblets. Gastrointest Endosc 1996; 44: 91.
16. Chandrasoma P. Controversies of the cardiac mucosa and Barrett's oesophagus. Histopathology 2005; 46: 361.
17. British Society of Gastroenterology. Guidelines for the diagnosis and management of Barrett's columnar-lined oesophagus. A Report of the Working Party of the British Society of Gastroenterology, August 2005. Available: www.bsg.org.uk.
18. Sharma P, Dent J, Armstrong D, et al. The development and validation of an endoscopic grading system for Barrett's esophagus: the Prague C & M criteria. Gastroenterology 2006; 131: 1392.
19. Correa P. Helicobacter pylori and gastric carcinogenesis. Am J Surg Pathol 1995; 19(Suppl 1): S37.
20. Spechler SJ. Intestinal metaplasia at the gastroesophageal junction. Gastroenterology 2004; 126: 567.
21. Sharma P, Weston AP, Morales, T, et al. Relative risk of dysplasia for patients with intestinal metaplasia in the distal oesophagus and in the gastric cardia. Gut 2000; 46: 9.
22. Sampliner RE and the Practice Parameters Committee of the American College of Gastroenterology. Updated guidelines for the diagnosis, surveillance, and therapy of Barrett's esophagus. Am J Gastroenterol 2002; 97: 1888.
23. Fennerty MB. Gastric intestinal metaplasia on routine endoscopic biopsy. Gastroenterology 2003; 125: 586.
24. Ormsby AH, Goldblum JR, Rice TW, et al. Cytokeratin subsets can reliably distinguish Barrett's esophagus from intestinal metaplasia of the stomach. Hum Pathol 1999; 30: 288.
25. Glickman JN, Wang H, Das KM, et al. Phenotype of Barrett's esophagus and intestinal metaplasia of the distal esophagus and gastroesophageal junction. An immunohistochemical study of cytokeratins 7 and 20, Das-1 and 45 MI. Am J Surg Pathol 2001; 25: 87.
26. Morales CP, Spechler SJ. Intestinal metaplasia at the gastroesophageal junction: Barrett's, bacteria, and biomarkers. Am J Gastroenterol 2003; 98: 759.
27. Cameron AJ. Epidemiology of columnar-lined esophagus and adenocarcinoma. Gastroenterol Clin N Am 1997; 26: 487.
28. Spechler SJ, Jain SK, Tendler DA, Parker RA. Racial differences in the frequency of symptoms and complications of gastrooesophageal reflux disease. Aliment Pharmacol Ther 2002; 16: 1795.
29. Rex DK, Cummings OW, Shaw M, et al. Screening for Barrett's esophagus in colonoscopy patients with and without heartburn. Gastroenterology 2003; 125: 1670.
30. Ronkainen J, Aro P, Storskrubb T, et al. Prevalence of Barrett's esophagus in the general population: an endoscopic study. Gastroenterology 2005; 129: 1825.
31. Hassall E. Esophageal metaplasia: definition and prevalence in childhood. Gastrointest Endosc 2006; 64: 676.
32. El-Serag HB, Gilger MA, Shub MD, et al. The prevalence of suspected Barrett's esophagus in children and adolescents: a multicenter endoscopic study. Gastrointest Endosc 2006; 64: 671.
33. Hassall E, Kerr W, El-Serag HB. Characteristics of children receiving proton pump inhibitors continuously for up to 11 years duration. J Pediatr 2007; 150: 262.
34. Blot WJ, Devesa SS, Kneller RW, Fraumeni JF, Jr. Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA 1991; 265: 1287.
35. Blot WJ, Devesa SS, Fraumeni JF, Jr. Continuing climb in rates of esophageal adenocarcinoma: an update. JAMA 1993; 270: 1320.
36. Hampel H, Abraham NS, El-Serag HB. Meta-analysis: obesity and the risk for gastroesophageal reflux disease and its complications. Ann Intern Med 2005; 143: 199.
37. Pandolfino JE, El-Serag HB, Zhang Q, et al. Obesity: a challenge to esophagogastric junction integrity. Gastroenterology 2006; 130: 639.
38. El-Serag HB, Ergun GA, Pandolfino J, et al. Obesity increases oesophageal acid exposure. Gut 2007; 56: 749.
39. Renehan AG, Frystyk J, Flyvbjerg A. Obesity and cancer risk: the role of the insulin-IGF axis. Trends Endocrinol Metab 2006; 17: 328.
40. Hoda MR, Keely SJ, Bertelsen LS, et al. Leptin acts as a mitogenic and antiapoptotic factor for colonic cancer cells. Br J Surg 2007; 94: 346.
41. Arditi JD, Venihaki M, Karalis KP, Chrousos GP. Antiproliferative effect of adiponectin on MCF7 breast cancer cells: a potential hormonal link between obesity and cancer. Horm Metab Res 2007; 39: 9.
42. El-Serag HB, Kvapil P, Hacken-Bitar J, Kramer JR. Abdominal obesity and the risk of Barrett's esophagus. Am J Gastroenterol 2005; 100: 2151.
43. Corley DA, Kubo A, Levin TR, et al. Abdominal obesity and body mass index as risk factors for Barrett's esophagus. Gastroenterology 2007; 133: 34.
44. Parsonnet J. The incidence of Helicobacter pylori infection. Aliment Pharmacol Ther 1995; 9(Suppl 2): 45.
45. Ye W, Held M, Lagergren J, et al. Helicobacter pylori infection and gastric atrophy: risk of adenocarcinoma and squamous-cell carcinoma of the esophagus and adenocarcinoma of the gastric cardia. J Natl Cancer Inst 2004; 96: 388.
46. Vicari JJ, Peek RM, Falk GW, et al. The seroprevalence of cagApositive Helicobacter pylori strains in the spectrum of gastroesophageal reflux disease. Gastroenterology 1998; 115: 50.
47. Delaney B, McColl K. Review article: Helicobacter pylori and gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2005; 22(Suppl 1): 32.
48. Corley DA, Kerlikowske K, Verma R, Buffler P. Protective association of aspirin/NSAIDs and esophageal cancer: a systematic review and meta-analysis. Gastroenterology 2003; 124: 47.
49. Terry P, Lagergren J, Hansen H, et al. Fruit and vegetable consumption in the prevention of oesophageal and cardia cancers. Eur. J Cancer Prev 2001; 10: 365.
50. Blot WJ, McLaughlin JK. The changing epidemiology of esophageal cancer. Semin Oncol 1999; 26(Suppl 15): 2.
51. Lagergren J. Adenocarcinoma of oesophagus: what exactly is the size of the problem and who is at risk? Gut 2005; 54(Suppl 1): 11.
52. Shaheen NJ, Crosby MA, Bozymski EM, Sandler RS. Is there publication bias in the reporting of cancer risk in Barrett's esophagus? Gastroenterology 2000; 119: 333.
53. Spechler SJ, Lee E, Ahnen D, et al. Long-term outcome of medical and surgical treatments for gastroesophageal reflux disease. Follow-up of a randomized controlled trial. JAMA 2001; 285: 2331.
54. Sharma P, Falk GW, Weston AP, et al. Dysplasia and cancer in a large multicenter cohort of patients with Barrett's esophagus. Clin Gastroenterol Hepatol 2006; 4: 566.
55. Hirota WK, Loughney TM, Lazas DJ, et al. Specialized intestinal metaplasia, dysplasia, and cancer of the esophagus and esophagogastric junction: prevalence and clinical data. Gastroenterology 1999; 116: 277.
56. Avidan B, Sonnenberg A, Schnell TG, et al. Hiatal hernia size, Barrett's length, and severity of acid reflux are all risk factors for esophageal adenocarcinoma. Am J Gastroenterol 2002; 97: 1930.
57. Rudolph RE, Vaughan TL, Storer BE, et al. Effect of segment length on risk for neoplastic progression in patients with Barrett esophagus. Ann Intern Med 2000; 132: 612.
58. Tosh D, Slack JM. How cells change their phenotype. Nat Rev Mol Cell Biol 2002; 3: 187.
59. Collen MJ, Lewis JH, Benjamin SB. Gastric acid hypersecretion in refractory gastroesophageal reflux disease. Gastroenterology 1990; 98: 654.
60. Gillen P, Keeling P, Byrne PJ, et al. Implication of duodenogastric reflux in the pathogenesis of Barrett's oesophagus. Br J Surg 1988; 75: 540.
61. Iascone C, DeMeester TR, Little AG, Skinner DB. Barrett's esophagus. Functional assessment, proposed pathogenesis, and surgical therapy. Arch Surg 1983; 118: 543.
62. Zaninotto G, DeMeester TR, Bremner CG, et al. Esophageal function in patients with reflux-induced strictures and its relevance to surgical treatment. Ann Thorac Surg 1989; 47: 362.
63. Johnson DA, Winters C, Spurling TJ, et al. Esophageal acid sensitivity in Barrett's esophagus. J Clin Gastroenterol 1987; 9: 23.
64. Gray MR, Donnelly RJ, Kingsnorth AN. Role of salivary epidermal growth factor in the pathogenesis of Barrett's columnar-lined oesophagus. Br J Surg 1991; 78: 1461.
65. Hirschowitz BI. Gastric acid and pepsin secretion in patients with Barrett's esophagus and appropriate controls. Dig Dis Sci 1996; 41: 1384.
66. Fletcher J, Wirz A, Young J, et al. Unbuffered highly acidic gastric juice exists at the gastroesophageal junction after a meal. Gastroenterology 2001; 121: 775.
67. Fletcher J, Wirz A, Henry E, McColl KEL. Studies of acid exposure immediately above the gastro-oesophageal junction: evidence of short segment reflux. Gut 2004; 53: 168.
68. Pandolfino JE, Lee TJ, Schreiner MA, et al. Comparison of esophageal acid exposure at 1 cm and 6 cm above the squamocolumnar junction using the Bravo pH monitoring system. Dis Esophagus 2006; 19: 177.
69. Iijima K, Henry E, Moriya A, et al. Dietary nitrate generates potentially mutagenic concentrations of nitric oxide at the gastroesophageal junction. Gastroenterology 2002; 122: 1248.
70. Spechler SJ. Are we underestimating acid reflux? Gut 2004; 53: 162.
71. Jankowski JA, Wright NA, Meltzer SJ, et al. Molecular evolution of the metaplasia-dysplasia-adenocarcinoma sequence in the esophagus. Am J Pathol 1999; 154: 965.
72. Glickman JN, Chen YY, Wang HH, et al. Phenotypic characteristics of a distinctive multilayered epithelium suggests that it is a precursor in the development of Barrett's esophagus. Am J Surg Pathol 2001; 25: 569.
73. Sarosi GA, Jr, Brown GA, Jaiswal K, et al. Bone marrow progenitor cells contribute to esophageal regeneration and metaplasia in a rat model of Barrett's esophagus. Dis Esophagus 2008; 21: 43.
74. Silberg DG, Sullivan J, Kang E, et al. Cdx2 ectopic expression induces gastric intestinal metaplasia in transgenic mice. Gastroenterology 2002; 122: 689.
75. Mutoh H, Sakurai S, Satoh K, et al. Cdx1-induced intestinal metaplasia in the transgenic mouse stomach: comparative study with Cdx2 transgenic mice. Gut 2004; 53: 1416.
76. Marchetti M, Caliot E, Pringault E. Chronic acid exposure leads to activation of the cdx2 intestinal homeobox gene in a long-term culture of mouse esophageal keratinocytes. J Cell Sci 2003; 116: 1429.
77. Pera M, de Bolas C, Brito MJ, et al. Duodenal-content reflux into the esophagus leads to expression of Cdx2 and Muc2 in areas of squamous epithelium in rats. J Gastrointest Surg 2007; 11: 869.
78. Moons LM, Bax DA, Kuipers EJ, et al. The homeodomain protein CDX2 is an early marker of Barrett's oesophagus. J Clin Pathol 2004; 57: 1063.
79. Wong NA, Wilding J, Bartlett S, et al. CDX1 is an important molecular mediator of Barrett's metaplasia. Proc Natl Acad Sci USA 2005; 102: 7565.
80. Phillips RW, Frierson HF, Jr, Moskaluk CA. Cdx2 as a marker of epithelial intestinal differentiation in the esophagus. Am J Surg Pathol 2003; 27: 1442.
81. Que J, Choi M, Ziel JW, et al. Morphogenesis of the trachea and esophagus: current players and new roles for noggin and Bmps. Differentiation 2006; 74: 422.
82. Milano F, van Baal JW, Buttar NS, et al. Bone morphogenetic protein 4 expressed in esophagitis induces a columnar phenotype in esophageal squamous cells. Gastroenterology 2007; 132: 2412.
83. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57.
84. Souza RF, Morales CP, Spechler SJ. Review article: a conceptual approach to understanding the molecular mechanisms of cancer development in Barrett's oesophagus. Aliment Pharmacol Ther 2001; 15: 1087.
85. Morales CP, Souza RF, Spechler SJ. Hallmarks of cancer progression in Barrett's oesophagus. Lancet 2002; 360: 1587.
86. Arber N, Gammon MD, Hibshoosh H, et al. Overexpression of cyclin D1 occurs in both squamous carcinomas and adenocarcinomas of the esophagus and in adenocarcinomas of the stomach. Hum Pathol 1999; 30: 1087.
87. Sarbia M, Bektas N, Muller W, et al. Expression of cyclin E in dysplasia, carcinoma, and nonmalignant lesions of Barrett esophagus. Cancer 1999; 86: 2597.
88. Lin L, Prescott MS, Zhu Z, et al. Identification and characterization of a 19q12 amplicon in esophageal adenocarcinomas reveals cyclin E as the best candidate gene for this amplicon. Cancer Res 2000; 60: 7021.
89. Geddert H, Heep HJ, Gabbert HE, Sarbia M. Expression of cyclin B1 in the metaplasia-dysplasia-carcinoma sequence of Barrett esophagus. Cancer 2002; 94: 212.
90. Sarbia M, Arjumand J, Wolter M, et al. Frequent c-myc amplification in high-grade dysplasia and adenocarcinoma in Barrett esophagus. Am J Clin Pathol 2001; 115: 835.
91. Tselepis C, Morris CD, Wakelin D, et al. Upregulation of the oncogene c-myc in Barrett's adenocarcinoma: induction of c-myc by acidified bile acid in vitro. Gut 2003; 52: 174.
92. Malumbres M, Pellicer A. RAS pathways to cell cycle control and cell transformation. Front Biosci 1998; 3: d887.
93. Sommerer F, Vieth M, Markwarth A, et al. Mutations of BRAF and KRAS2 in the development of Barrett's adenocarcinoma. Oncogene 2004; 23: 554.
94. Jankowski J, McMenemin R, Hopwood D, et al. Abnormal expression of growth regulatory factors in Barrett's oesophagus. Clin Sci (Colch) 1991; 81: 663.
95. Haigh CR, Attwood SE, Thompson DG, et al. Gastrin induces proliferation in Barrett's metaplasia through activation of the CCK2 receptor. Gastroenterology 2003; 124: 615.
96. Harris JC, Clarke PA, Awan A, et al. An antiapoptotic role for gastrin and the gastrin/CCK-2 receptor in Barrett's esophagus. Cancer Res 2004; 64: 1915.
97. Souza RF, Shewmake K, Terada LS, Spechler SJ. Acid exposure activates the mitogen-activated protein kinase pathways in Barrett's esophagus. Gastroenterology 2002; 122: 299.
98. Jaiswal K, Lopez-Guzman C, Souza RF, et al. Bile salt exposure increases proliferation through p38 and ERK MAPK pathways in a non-neoplastic Barrett's cell line. Am J Physiol Gastrointest Liver Physiol 2006; 290: G335.
99. Feagins LA, Susnow N, Zhang HY, et al. Gain of allelic gene expression for IGF-II occurs frequently in Barrett's esophagus. Am J Physiol Gastrointest Liver Physiol 2006; 290: G871.
100. Iravani S, Zhang HQ, Yuan ZQ, et al. Modification of insulin-like growth factor 1 receptor, c-Src, and Bcl-XL protein expression during the progression of Barrett's neoplasia. Hum Pathol 2003; 34: 975.
101. Herrera LJ, El Hefnawy T, Queiroz de Oliveira PE, et al. The HGF receptor c-Met is overexpressed in esophageal adenocarcinoma. Neoplasia 2005; 7: 75.
102. Flejou JF, Paraf F, Muzeau F, et al. Expression of c-erbB-2 oncogene product in Barrett's adenocarcinoma: pathological and prognostic correlations. J Clin Pathol 1994; 47: 23.
103. Brien TP, Odze RD, Sheehan CE, et al. HER-2/neu gene amplification by FISH predicts poor survival in Barrett's esophagus-associated adenocarcinoma. Hum Pathol 2000; 31: 35.
104. Blount PL, Galipeau PC, Sanchez CA, et al. 17p allelic losses in diploid cells of patients with Barrett's esophagus who develop aneuploidy. Cancer Res 1994; 54: 2292.
105. Barrett MT, Sanchez CA, Prevo LJ, et al. Evolution of neoplastic cell lineages in Barrett oesophagus. Nat Genet 1999; 22: 106.
106. Younes M, Lebovitz RM, Lechago LV, Lechago J. p53 protein accumulation in Barrett's metaplasia, dysplasia, and carcinoma: a follow-up study. Gastroenterology 1993; 105: 1637.
107. Hamelin R, Flejou JF, Muzeau F, et al. TP53 gene mutations and p53 protein immunoreactivity in malignant and premalignant Barrett's esophagus. Gastroenterology 1994; 107: 1012.
108. Rioux-Leclercq N, Turlin B, Sutherland F, et al. Analysis of Ki-67, p53 and Bcl-2 expression in the dysplasia-carcinoma sequence of Barrett's esophagus. Oncol Rep 1999; 6: 877.
109. Meltzer SJ, Yin J, Huang Y, et al. Reduction to homozygosity involving p53 in esophageal cancers demonstrated by the polymerase chain reaction. Proc Natl Acad Sci USA 1991; 88: 4976.
110. Barrett MT, Sanchez CA, Galipeau PC, et al. Allelic loss of 9p21 and mutation of the CDKN2/p16 gene develop as early lesions during neoplastic progression in Barrett's esophagus. Oncogene 1996; 13: 1867.
111. Wong DJ, Barrett MT, Stoger R, et al. p16INK4a promoter is hyper-methylated at a high frequency in esophageal adenocarcinomas. Cancer Res 1997; 57: 2619.
112. Barrett MT, Galipeau PC, Sanchez CA, et al. Determination of the frequency of loss of heterozygosity in esophageal adenocarcinoma by cell sorting, whole genome amplification and microsatellite polymorphisms. Oncogene 1996; 12: 1873.
113. Maley CC, Galipeau PC, Li X, et al. The combination of genetic instability and clonal expansion predicts progression to esophageal adenocarcinoma. Cancer Res 2004; 64: 7629.
114. Singh SP, Lipman J, Goldman H, et al. Loss or altered subcellular localization of p27 in Barrett's associated adenocarcinoma. Cancer Res 1998; 58: 1730.
115. Dolan K, Garde J, Walker SJ, et al. LOH at the sites of the DCC, APC, and TP53 tumor suppressor genes occurs in Barrett's metaplasia and dysplasia adjacent to adenocarcinoma of the esophagus. Hum Pathol 1999; 30: 1508.
116. Powell SM, Papadopoulos N, Kinzler KW, et al. APC gene mutations in the mutation cluster region are rare in esophageal cancers. Gastroenterology 1994; 107: 1759.
117. Eads CA, Lord RV, Kurumboor SK, et al. Fields of aberrant CpG island hypermethylation in Barrett's esophagus and associated adenocarcinoma. Cancer Res 2000; 60: 5021.
118. Clement G, Braunschweig R, Pasquier N, et al. Methylation of APC, TIMP3, and TERT: a new predictive marker to distinguish Barrett's oesophagus patients at risk for malignant transformation. J Pathol 2006; 208: 100.
119. Kawakami K, Brabender J, Lord RV, et al. Hypermethylated APC DNA in plasma and prognosis of patients with esophageal adenocarcinoma. J Natl Cancer Inst 2000; 92: 1805.
120. Vermeulen K, Van Bockstaele DR, Berneman ZN. Apoptosis: mechanisms and relevance in cancer. Ann Hematol 2005; 84: 627.
121. Hetts SW. To die or not to die: an overview of apoptosis and its role in disease. JAMA 1998; 279: 300.
122. Tselepis C, Perry I, Dawson C, et al. Tumour necrosis factor-alpha in Barrett's oesophagus: a potential novel mechanism of action. Oncogene 2002; 21: 6071.
123. Ashkenazi A, Dixit VM. Death receptors: signaling and modulation. Science 1998; 281: 1305.
124. Hsu H, Shu HB, Pan MG, Goeddel DV. TRADD-TRAF2 and TRADDFADD interactions define two distinct TNF receptor 1 signal transduction pathways. Cell 1996; 84: 299.
125. Li-Weber M, Krammer PH. Function and regulation of the CD95 (APO-1/Fas) ligand in the immune system. Semin Immunol 2003; 15: 145.
126. van der Woude CJ, Jansen PL, Tiebosch AT, et al. Expression of apoptosis-related proteins in Barrett's metaplasia-dysplasia-carcinoma sequence: a switch to a more resistant phenotype. Hum Pathol 2002; 33: 686.
127. Hughes SJ, Nambu Y, Soldes OS, et al. Fas/APO-1 (CD95) is not translocated to the cell membrane in esophageal adenocarcinoma. Cancer Res 1997; 57: 5571.
128. Younes M, Lechago J, Ertan A, et al. Decreased expression of Fas (CD95/APO1) associated with goblet cell metaplasia in Barrett's esophagus. Hum Pathol 2000; 31: 434.
129. Igney FH, Krammer PH. Tumor counterattack: fact or fiction? Cancer Immunol Immunother 2005; 54: 1127.
130. Younes M, Schwartz MR, Ertan A, et al. Fas ligand expression in esophageal carcinomas and their lymph node metastases. Cancer 2000; 88: 524.
131. Katada N, Hinder RA, Smyrk TC, et al. Apoptosis is inhibited early in the dysplasia-carcinoma sequence of Barrett esophagus. Arch Surg 1997; 132: 728.
132. Raouf AA, Evoy DA, Carton E, et al. Loss of Bcl-2 expression in Barrett's dysplasia and adenocarcinoma is associated with tumor progression and worse survival but not with response to neoadjuvant chemoradiation. Dis Esophagus 2003; 16: 17.
133. Shureiqi I, Xu X, Chen D, et al. Nonsteroidal anti-inflammatory drugs induce apoptosis in esophageal cancer cells by restoring 15lipoxygenase-1 expression. Cancer Res 2001; 61: 4879.
134. Tsujii M, DuBois RN. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 1995; 83: 493.
135. Wilson KT, Fu S, Ramanujam KS, Meltzer SJ. Increased expression of inducible nitric oxide synthase and cyclooxygenase-2 in Barrett's esophagus and associated adenocarcinomas. Cancer Res 1998; 58: 2929.
136. Zimmermann KC, Sarbia M, Weber AA, et al. Cyclooxygenase-2 expression in human esophageal carcinoma. Cancer Res 1999; 59: 198.
137. Souza R.F., Shewmake K, Beer DG, et al. Selective inhibition of cyclooxygenase-2 suppresses growth and induces apoptosis in human esophageal adenocarcinoma cells. Cancer Res 2000; 60: 5767.
138. Abdel-latif MM, O'Riordan J, Windle HJ, et al. NF-kappaB activation in esophageal adenocarcinoma: relationship to Barrett's metaplasia, survival, and response to neoadjuvant chemoradiotherapy. Ann Surg 2004; 239: 491.
139. O'Riordan JM, Abdel-latif MM, Ravi N, et al. Proinflammatory cytokine and nuclear factor kappa-B expression along the inflammation-metaplasia-dysplasia-adenocarcinoma sequence in the esophagus. Am J Gastroenterol 2005; 100: 1257.
140. Blasco MA. Telomeres and human disease: ageing, cancer and beyond. Nat Rev Genet 2005; 6: 611.
141. Shay JW, Bacchetti S. A survey of telomerase activity in human cancer. Eur J Cancer 1997; 33: 787.
142. Collins K, Mitchell JR. Telomerase in the human organism. Oncogene 2002; 21: 564.
143. Lord RV, Salonga D, Danenberg KD, et al. Telomerase reverse transcriptase expression is increased early in the Barrett's metaplasia, dysplasia, adenocarcinoma sequence. J Gastrointest Surg 2000; 4: 135.
144. Morales CP, Lee EL, Shay JW. In situ hybridization for the detection of telomerase RNA in the progression from Barrett's esophagus to esophageal adenocarcinoma. Cancer 1998; 83: 652.
145. Palanca-Wessels MC, Barrett MT, Galipeau PC, et al. Genetic analysis of long-term Barrett's esophagus epithelial cultures exhibiting cytogenetic and ploidy abnormalities. Gastroenterology 1998; 114: 295.
146. Jaiswal KR, Morales CP, Feagins LA, et al. Characterization of telomerase-immortalized, non-neoplastic, human Barrett's cell line (BAR-T). Dis Esophagus 2007; 20: 256.
147. Shammas MA, Koley H, Beer DG, et al. Growth arrest, apoptosis, and telomere shortening of Barrett's-associated adenocarcinoma cells by a telomerase inhibitor. Gastroenterology 2004; 126: 1337.
148. Byrne AM, Bouchier-Hayes DJ, Harmey JH. Angiogenic and cell survival functions of vascular endothelial growth factor (VEGF). J Cell Mol Med 2005; 9: 777.
149. Kleespies A, Guba M, Jauch KW, Bruns CJ. Vascular endothelial growth factor in esophageal cancer. J Surg Oncol 2004; 87: 95.
150. Auvinen MI, Sihvo EI, Ruohtula T, et al. Incipient angiogenesis in Barrett's epithelium and lymphangiogenesis in Barrett's adenocarcinoma. J Clin Oncol 2002; 20: 2971.
151. Couvelard A, Paraf F, Gratio V, et al. Angiogenesis in the neoplastic sequence of Barrett's oesophagus. Correlation with VEGF expression. J Pathol 2000; 192: 14.
152. Sihvo EI, Ruohtula T, Auvinen MI, et al. Simultaneous progression of oxidative stress and angiogenesis in malignant transformation of Barrett esophagus. J Thorac Cardiovasc Surg 2003; 126: 1952.
153. Mobius C, Stein HJ, Becker I, et al. The "angiogenic switch" in the progression from Barrett's metaplasia to esophageal adenocarcinoma. Eur J Surg Oncol 2003; 29: 890.
154. von Rahden BH, Stein HJ, Puhringer F, et al. Coexpression of cyclooxygenases (COX-1, COX-2) and vascular endothelial growth factors (VEGF-A, VEGF-C) in esophageal adenocarcinoma. Cancer Res 2005; 65: 5038.
155. Lord RV, Park JM, Wickramasinghe K, et al. Vascular endothelial growth factor and basic fibroblast growth factor expression in esophageal adenocarcinoma and Barrett esophagus. J Thorac Cardiovasc Surg 2003; 125: 246.
156. Behrens J. Cell contacts, differentiation, and invasiveness of epithelial cells. Invasion Metastasis 1994; 14: 61.
157. Seery JP, Syrigos KN, Karayiannakis AJ, et al. Abnormal expression of the E-cadherin-catenin complex in dysplastic Barrett's oesophagus. Acta Oncol 1999; 38: 945.
158. Bian YS, Osterheld MC, Bosman FT, et al. Nuclear accumulation of beta-catenin is a common and early event during neoplastic progression of Barrett esophagus. Am J Clin Pathol 2000; 114: 583.
159. Washington K, Chiappori A, Hamilton K, et al. Expression of betacatenin, alpha-catenin, and E-cadherin in Barrett's esophagus and esophageal adenocarcinomas. Mod Pathol 1998; 11: 805.
160. Bailey T, Biddlestone L, Shepherd N, et al. Altered cadherin and catenin complexes in the Barrett's esophagus-dysplasia-adenocarcinoma sequence: correlation with disease progression and dedifferentiation. Am J Pathol 1998; 152: 135.
161. Coussens LM, Fingleton B, Matrisian LM. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 2002; 295: 2387.
162. Pender SL, MacDonald TT. Matrix metalloproteinases and the gut -new roles for old enzymes. Curr Opin Pharmacol 2004; 4: 546.
163. Salmela MT, Karjalainen-Lindsberg ML, Puolakkainen P, Saarialho-Kere U. Upregulation and differential expression of matrilysin (MMP-7) and metalloelastase (MMP-12) and their inhibitors TIMP-1 and TIMP-3 in Barrett's oesophageal adenocarcinoma. Br J Cancer 2001; 85: 383.
164. Spechler SJ. Dysplasia in Barrett's esophagus: limitations of current management strategies. Am J Gastroenterol 2005; 100: 927.
165. Hamilton SR, Aaltonen LA (eds). World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of the Digestive System. Lyon: IARC Press, 2000.
166. Goldblum JR. Barrett's esophagus and Barrett's-related dysplasia. Mod Pathol 2003; 16: 316.
167. Reid BJ, Haggitt RC, Rubin CE. Observer variation in the diagnosis of dysplasia in Barrett's esophagus. Hum Pathol 1988; 19: 166.
168. Skacel M, Petras RE, Gramlich TL, et al. The diagnosis of low-grade dysplasia in Barrett's esophagus and its implications for disease progression. Am J Gastroenterol 2000; 95: 3383.
169. Montgomery E, Bronner MP, Goldblum JR, et al. Reproducibility of the diagnosis of dysplasia in Barrett esophagus: a reaffirmation. Hum Pathol 2001; 32: 368.
170. Ormsby AH, Petras RE, Henricks WH, et al. Observer variation in the diagnosis of superficial oesophageal adenocarcinoma. Gut 2002; 51: 671.
171. Reid BJ, Weinstein WM, Lewin KJ, et al. Endoscopic biopsy can detect high-grade dysplasia or early adenocarcinoma in Barrett's esophagus without grossly recognizable neoplastic lesions. Gastroenterology 1988; 94: 81.
172. Cameron AJ, Carpenter HA. Barrett's esophagus, high-grade dysplasia, and early adenocarcinoma: a pathological study. Am J Gastroenterol 1997; 92: 586.
173. Collard JM. High-grade dysplasia in Barrett's esophagus. The case for esophagectomy. Chest Surg Clin North Am 2002; 12: 77.
174. Levine DS, Haggitt RC, Blount PL, et al. An endoscopic biopsy protocol can differentiate high-grade dysplasia from early adenocarcinoma in Barrett's esophagus. Gastroenterology 1993; 105: 40.
175. Reid BJ, Blount PL, Rabinovitch PS. Biomarkers in Barrett's esophagus. Gastrointest Endosc Clin N Am 2003; 13: 369.
176. Scotiniotis IA, Kochman ML, Lewis JD, et al. Accuracy of EUS in the evaluation of Barrett's esophagus and high-grade dysplasia or intramucosal carcinoma. Gastrointest Endosc 2001; 54: 689.
177. Kobayashi K, Izatt JA, Kulkarni MD, et al. High-resolution cross-sectional imaging of the gastrointestinal tract using optical coherence tomography: preliminary results. Gastrointest Endosc 1998; 47: 515.
178. Georgakoudi I, Jacobson BC, Van Dam J, et al. Fluorescence, reflectance, and light-scattering spectroscopy for evaluating dysplasia in patients with Barrett's esophagus. Gastroenterology 2001; 120: 1620.
179. Kendall C, Stone N, Shepherd N, et al. Raman spectroscopy, a potential tool for the objective identification and classification of neoplasia in Barrett's oesophagus. J Pathol 2003; 200: 602.
180. Skacel M, Petras RE, Rybicki LA, et al. p53 expression in low grade dysplasia in Barrett's esophagus: correlation with interobserver agreement and disease progression. Am J Gastroenterol 2002; 97: 2508.
181. Bani-Hani K, Martin IG, Hardie LJ, et al. Prospective study of cyclin D1 overexpression in Barrett's esophagus: association with increased risk of adenocarcinoma. J Natl Cancer Inst 2000; 92: 1316.
182. Reid BJ, Levine DS, Longton G, et al. Predictors of progression to cancer in Barrett's esophagus: baseline histology and flow cytometry identify low-and high-risk patient subsets. Am J Gastroenterol 2000; 95: 1669.
183. Schnell TG, Sontag SJ, Chejfec G, et al. Long-term nonsurgical management of Barrett's esophagus with high-grade dysplasia. Gastroenterology 2001; 120: 1607.
184. O'Connor JB, Falk GW, Richter JE. The incidence of adenocarcinoma and dysplasia in Barrett's esophagus. Report on the Cleveland Clinic Barrett's esophagus registry. Am J Gastroenterol 1999; 94: 2037.
185. Weston AP, Banerjee SK, Sharma P, et al. p53 protein overexpression in low grade dysplasia (LGD) in Barrett's esophagus: immunohistochemical marker predictive of progression. Am J Gastroenterol 2001; 96: 1355.
186. Hameeteman W, Tytgat GNJ, Houthoff HJ, van den Tweel JG. Barrett's esophagus: development of dysplasia and adenocarcinoma. Gastroenterology 1989; 96: 1249.
187. Spechler SJ. Disputing dysplasia. Gastroenterology 2001; 120: 1864.
188. Buttar NS, Wang KK, Sebo TJ, et al. Extent of high grade dysplasia in Barrett's esophagus correlates with risk of adenocarcinoma. Gastroenterology 2001; 120: 1630.
189. Dar MS, Goldblum JR, Rice TW, Falk GW. Can extent of high grade dysplasia in Barrett's oesophagus predict the presence of adenocarcinoma at oesophagectomy? Gut 2003; 52: 486.
190. Weston AP, Sharma Prateek S, Topalovski M, et al. Long-term follow-up of Barrett's high-grade dysplasia. Am J Gastroenterol 2000; 95: 1888.
191. DeVault KR, Castell DO; American College of Gastroenterology. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol 2005; 100: 190.
192. Fitzgerald RC, Omary MB, Triadafilopoulos G. Dynamic effects of acid on Barrett's esophagus. An ex vivo proliferation and differentiation model. J Clin Invest 1996; 98: 2120.
193. Shirvani VN, Ouatu-Lascar R, Kaur BS, et al. Cyclooxgenase 2 expression in Barrett's esophagus and adenocarcinoma: ex vivo induction by bile salts and acid exposure. Gastroenterology 2000; 118: 487.
194. Souza RF, Shewmake K, Terada LS, Spechler SJ. Acid exposure activates the mitogen activated protein kinase pathways in Barrett's esophagus. Gastroenterology 2002; 122: 299.
195. Ouatu-Lascar R, Fitzgerald RC, Triadafilopoulos G. Differentiation and proliferation in Barrett's esophagus and the effects of acid suppression. Gastroenterology 1999; 117: 327.
196. Peters FT, Ganesh S, Kuipers EJ, et al. Effect of elimination of acid reflux on epithelial cell proliferative activity of Barrett esophagus. Scand J Gastroenterol 2000; 35: 1238.
197. Srinivasan R, Katz PO, Ramakrishnan A, et al. Maximal acid reflux control for Barrett's oesophagus: feasible and effective. Aliment Pharmacol Ther 2001; 15: 519.
198. Garewal H, Ramsey L, Sharma P, et al. Biomarker studies in reversed Barrett's esophagus. Am J Gastroenterol 1999; 94: 2829.
199. El-Serag HB, Aguirre TV, Davis S, et al. Proton pump inhibitors are associated with reduced incidence of dysplasia in Barrett's esophagus. Am J Gastroenterol 2004; 99: 1877.
200. Feagins LA, Zhang HY, Hormi-Carver K, et al. Acid has antiproliferative effects in nonneoplastic Barrett's epithelial cells. Am J Gastroenterol 2007; 102: 10.
201. Katzka DA, Castell DO. Successful elimination of reflux symptoms does not ensure adequate control of acid reflux in patients with Barrett's esophagus. Am J Gastroenterol 1994; 89: 989.
202. Yeh RW, Gerson LB, Triadafilopoulos G. Efficacy of esomeprazole in controlling reflux symptoms, intraesophageal, and intragastric pH in patients with Barrett's esophagus. Dis Esophagus 2003; 16: 193.
203. Gerson LB, Boparai V, Ullah N, et al. Oesophageal and gastric pH profiles in patients with gastro-oesophageal reflux disease and Barrett's oesophagus treated with proton pump inhibitors. Aliment Pharmacol Ther 2004; 20: 637.
204. Malfertheiner P, Lind T, Willich S, et al. Prognostic influence of Barrett's oesophagus and Helicobacter pylori infection on healing of erosive gastro-oesophageal reflux disease (GORD) and symptom resolution in non-erosive GORD: report from the ProGORD study. Gut 2005; 54: 746.
205. Spechler SJ, Sharma P, Traxler B, et al. Gastric and esophageal pH in patients with Barrett's esophagus treated with three esomeprazole dosages: a randomized, double-blind, crossover trial. Am J Gastroenterol 2006; 101: 1964.
206. DeMeester SR, DeMeester TR. Columnar mucosa and intestinal metaplasia of the esophagus. Fifty years of controversy. Ann Surg 2000; 231: 303.
207. Theisen J, Nehra D, Citron D, et al. Suppression of gastric acid secretion in patients with gastroesophageal reflux disease results in gastric bacterial overgrowth and deconjugation of bile acids. J Gastrointest Surg 2000; 4: 50.
208. Kauer WKH, Peters JH, DeMeester TR, et al. Mixed reflux of gastric and duodenal juices is more harmful to the esophagus than gastric juice alone. The need for surgical therapy re-emphasized. Ann Surg 1995; 222: 525.
209. Wetscher GJ, Hinder RA, Smyrk T, et al. Gastric acid blockade with omeprazole promotes gastric carcinogenesis induced by duodenogastric reflux. Dig Dis Sci 1999; 44: 1132.
210. Chow WH, Findkle WD, McLaughlin JK, et al. The relation of gastroesophageal reflux disease and its treatment to adenocarcinomas of the esophagus and gastric cardia. JAMA 1995; 274: 474.
211. Garrow DC, Vaughan TL, Sweeney C, et al. Gastroesophageal reflux disease, use of H2 receptor antagonists, and risk of esophageal and gastric cancer. Cancer Causes Control 2000; 11: 231.
212. Oberg S, Wenner J, Johansson J, et al. Barrett esophagus: risk factors for progression to dysplasia and adenocarcinoma. Ann Surg 2005; 242: 49.
213. Spechler SJ, Lee E, Ahnen D, et al. Long-term outcome of medical and surgical treatments for gastroesophageal reflux disease. Follow-up of a randomized controlled trial. JAMA 2001; 285: 2331.
214. Ye W, Chow WH, Lagergren J, et al. Risk of adenocarcinoma of the esophagus and gastric cardia in patients with gastroesophageal reflux diseases and after antireflux surgery. Gastroenterology 2001; 121: 1286.
215. Tran T, Spechler SJ, El-Serag HB. Fundoplication and the risk of cancer in gastroesophageal reflux disease: a veterans affairs cohort study. Am J Gastroenterol 2005; 100: 1002.
216. Corey KE, Schmitz SM, Shaheen NJ. Does a surgical antireflux procedure decrease the incidence of esophageal adenocarcinoma in Barrett's esophagus? A meta-analysis. Am J Gastroenterol 2003; 98: 2390.
217. Chang EY, Morris CD, Seltman AK, et al. The effect of antireflux surgery on esophageal carcinogenesis in patients with Barrett esophagus: a systematic review. Ann Surg 2007; 246: 11.
218. Eckardt VF, Kanzler G, Bernhard G. Life expectancy and cancer risk in patients with Barrett's esophagus: a prospective controlled investigation. Am J Med 2001; 111: 33.
219. Anderson LA, Murray LJ, Murphy SJ, et al. Mortality in Barrett's oesophagus: results from a population-based study. Gut 2003; 52: 1081.
220. Solaymani-Dodaran M, Logan RF, West J, Card T. Mortality associated with Barrett's esophagus and gastroesophageal reflux disease diagnoses -a population-based cohort study. Am J Gastroenterol 2005; 100: 2616.
221. Corley DA, Levin TR, Habel LA, et al. Surveillance and survival in Barrett's adenocarcinomas: a population-based study. Gastroenterology 2002; 122: 633.
222. Shaheen NJ, Provenzale D, Sandler RS. Upper endoscopy as a screening and surveillance tool in esophageal adenocarcinoma: a review of the evidence. Am J Gastroenterol 2002; 97: 1319.
223. Peters JH, Clark GWB, Ireland AP, et al. Outcome of adenocarcinoma arising in Barrett's esophagus in endoscopically surveyed and nonsurveyed patients. J Thorac Cardiovasc Surg 1994; 108: 813.
224. Macdonald CE, Wicks AC, Playford RJ. Final results from 10 year cohort of patients undergoing surveillance for Barrett's oesophagus: observational study. Br Med J 2000; 321: 1252.
225. Provenzale D, Schmitt C, Wong JB. Barrett's esophagus: a new look at surveillance based on emerging estimates of cancer risk. Am J Gastroenterol 1999; 94: 2043.
226. Soni A, Sampliner RE, Sonnenberg A. Screening for high-grade dysplasia in gastroesophageal reflux disease: is it cost-effective? Am J Gastroenterol 2000; 95: 2086.
227. Sonnenberg A, Soni A, Sampliner RE. Medical decision analysis of endoscopic surveillance of Barrett's oesophagus to prevent oesophageal adenocarcinoma. Aliment Pharmacol Ther 2002; 16: 41.
228. Inadomi JM, Sampliner R, Lagergren J, et al. Screening and surveillance for Barrett esophagus in high-risk groups: a cost-utility analysis. Ann Intern Med 2003; 138: 176.
229. Gerson LB, Groeneveld PW, Triadafilopoulos G. Cost-effectiveness model of endoscopic screening and surveillance in patients with gastroesophageal reflux disease. Clin Gastroenterol Hepatol 2004; 2: 868.
230. Hur C, Nishioka NS, Gazelle GS. Cost-effectiveness of aspirin chemoprevention for Barrett's esophagus. J Natl Cancer Inst 2004; 96: 316.
231. Rubenstein JH, Inadomi JM, Brill JV, Eisen GM. Cost utility of screening for Barrett's esophagus with esophageal capsule endoscopy versus conventional upper endoscopy. Clin Gastroenterol Hepatol 2007; 5: 312.
232. Gerson L, Lin OS. Cost-benefit analysis of capsule endoscopy compared with standard upper endoscopy for the detection of Barrett's esophagus. Clin Gastroenterol Hepatol 2007; 5: 319.
233. Swisher SG, DeFord L, Merriman KW, et al. Effects of operative volume on morbidity, mortality, and hospital use after esophagectomy for cancer. J Thorac Cardiovasc Surg 2000; 119: 1126.
234. Van Lanschot JJB, Hulscher JBF, Buskens CJ, et al. Hospital volume and hospital mortality for esophagectomy. Cancer 2001; 91: 1574.
235. Karl RC, Schreiber R, Boulware D, et al. Factors affecting morbidity, mortality, and survival in patients undergoing Ivor-Lewis esophagogastrectomy. Ann Surg 2000; 231: 635.
236. Young MM, Deschamps C, Trastek VF, et al. Esophageal reconstruction for benign disease: early morbidity, mortality, and functional results. Ann Thorac Surg 2000; 70: 1651.
237. Nguyen NT, Schauer P, Luketich JD. Minimally invasive esophagectomy for Barrett's esophagus with high-grade dysplasia. Surgery 2000; 127: 284.
238. Luketich JD, Alvelo-Rivera M, Buenaventura PO, et al. Minimally invasive esophagectomy: outcomes in 222 patients. Ann Surg 2003; 238: 486.
239. Headrick JR, Nichols FC, III, Miller DL, et al. High-grade esophageal dysplasia: long-term survival and quality of life after esophagectomy. Ann Thorac Surg 2002; 73: 1697.
240. de Boer AG, van Lanschot JJ, van Sandick JW, et al. Quality of life after transhiatal compared with extended transthoracic resection for adenocarcinoma of the esophagus. J Clin Oncol 2004; 22: 4202.
241. Van den Boogert J, van Hillegersberg R, Siersema PD, et al. Endoscopic ablation therapy for Barrett's esophagus with high-grade dysplasia: a review. Am J Gastroenterol 1999; 94: 1153.
242. Sampliner RE. Endoscopic ablative therapy for Barrett's esophagus. Gastrointest Endosc 2004; 59: 66.
243. Bergman JJ. Latest developments in the endoscopic management of gastroesophageal reflux disease and Barrett's esophagus: an overview of the year's literature. Endoscopy 2006; 8: 122.
244. Sharma VK, Wang KK, Overholt BF, et al. Balloon-based, circumferential, endoscopic radiofrequency ablation of Barrett's esophagus: 1-year follow-up of 100 patients. Gastrointest Endosc 2007; 65: 185.
245. Van Laethem JL, Peny MO, Salmon I, et al. Intramucosal adenocarcinoma arising under squamous re-epithelialisation of Barrett's oesophagus. Gut 2000; 46: 574.
246. Garewal HS, Ramsey L, Sampliner RE, et al. Post-ablation biomarker abnormalities in Barrett's esophagus (BE): are we increasing the cancer risk? Gastroenterology 2001; 120: A79.
247. Bergman JJ. Radiofrequency energy ablation of Barrett's esophagus: the best is yet to come! Gastrointest Endosc 2007; 65: 200.
248. Overholt BF, Lightdale CJ, Wang KK, et al.; International Photo-dynamic Group for High-Grade Dysplasia in Barrett's Esophagus. Photodynamic therapy with porfimer sodium for ablation of high-grade dysplasia in Barrett's esophagus: international, partially blinded, randomized phase III trial. Gastrointest Endosc 2005; 62: 488.
249. Overholt BF, Wang KK, Burdick JS, et al.; on behalf of the International Photodynamic Group for High-Grade Dysplasia in Barrett's Esophagus. Five-year efficacy and safety of photodynamic therapy with Photofrin in Barrett's high-grade dysplasia. Gastrointest Endosc 2007 [Epub ahead of print].
250. Pouw RE, Gondrie JJ, Sondermeijer C, et al. Novel combined modality therapy for Barrett's esophagus containing high-grade dysplasia: endoscopic mucosal resection followed by circumferential and focal ablation using the HALO system. Gastrointest Endosc 2007; 65: AB111.
251. Soetikno RM, Gotoda T, Nakanishi Y, Soehendra N. Endoscopic mucosal resection. Gastrointest Endosc 2003; 57: 567.
252. Pech O, May A, Gossner L, et al. Management of pre-malignant and malignant lesions by endoscopic resection. Best Pract Res Clin Gastroenterol 2004; 18: 61.
253. Peters FP, Kara MA, Curvers WL, et al. Multiband mucosectomy for endoscopic resection of Barrett's esophagus: feasibility study with matched historical controls. Eur J Gastroenterol Hepatol 2007; 19: 311.
254. Rice TW, Zuccaro G, Adelstein DJ, et al. Esophageal carcinoma: depth of tumor invasion is predictive of regional lymph node status. Ann Thorac Surg 1998; 65: 787.
255. Feith M, Stein HJ, Siewert JR. Pattern of lymphatic spread of Barrett's cancer. World J Surg 2003; 27: 1052.
256. Siewert JR, Stein HJ. Lymph-node dissection in squamous cell esophageal cancer -who benefits? Langenbeck's Arch Surg 1999; 384: 141.
257. Prasad GA, Buttar NS, Wongkeesong LM, et al. Significance of neoplastic involvement of margins obtained by endoscopic mucosal resection in Barrett's esophagus. Am J Gastroenterol 2007 [Epub ahead of print].
258. Buttar NS, Wang KK, Lutzke LS, et al. Combined endoscopic mucosal resection and photodynamic therapy for esophageal neoplasia within Barrett's esophagus. Gastrointest Endosc 2001; 54: 682.
259. May A, Gossner L, Pech O, et al. Local endoscopic therapy for intraepithelial high-grade neoplasia and early adenocarcinoma in Barrett's oesophagus: acute-phase and intermediate results of a new treatment approach. Eur J Gastroenterol Hepatol 2002; 14: 1085.
260. Ell C, May A, Pech O, et al. Curative endoscopic resection of early esophageal adenocarcinomas (Barrett's cancer). Gastrointest Endosc 2007; 65: 3.
261. Prasad GA, Wang KK, Buttar NS, et al. Long-term survival following endoscopic and surgical treatment of high-grade dysplasia in Barrett's esophagus. Gastroenterology 2007; 132: 1226.
262. Lewis J, Lutzke L, Smyrk T, Wang K. The limitations of mucosal resection in Barrett's esophagus. Gastrointest Endosc 2004; 59: AB101.
263. Reid BJ, Blount PL, Feng Z, Levine DS. Optimizing endoscopic biopsy detection of early cancers in Barrett's high-grade dysplasia. Am J Gastroenterol 2000; 95: 3089.
264. Lightdale CJ. A balancing view: an individualized approach to high-grade dysplasia is key: esophagectomy, surveillance, or endoscopic therapy should all be considered. Am J Gastroenterol 2006; 101: 2183.
265. Corley DA, Kerlikowske K, Verma R, Buffler P. Protective association of aspirin/NSAIDs and esophageal cancer: a systematic review and meta-analysis. Gastroenterology 2003; 124: 47.
266. Wilson KT, Fu S, Ramanujam KS, Meltzer SJ. Increased expression of inducible nitric oxide synthase and cyclooxygenase-2 in Barrett's esophagus and associated adenocarcinomas. Cancer Res 1998; 58: 2929.
267. Buttar NS, Wang KK, Leontovich O, et al. Chemoprevention of esophageal adenocarcinoma by COX-2 inhibitors in an animal model of Barrett's esophagus. Gastroenterology 2002; 122: 1101.